penpulimab

Overview

Penpulimab is an anti-PD-1 monoclonal antibody targeting PDCD1. It is approved and recommended by NCCN guidelines (with toripalimab) as part of first-line combination regimens with platinum-based chemotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC).

Evidence in the corpus

  • Penpulimab (anti-PD-1) + platinum/gemcitabine is NCCN-recommended first-line standard for R/M NPC alongside toripalimab; ICI added on progression if not given upfront PMID:24952746.
  • Phase III tagitanlimab (anti-PD-L1) + gem/cis in R/M NPC (NCT05294172, n=358): PFS HR 0.47; ORR 81.7%; median DOR 11.7 months; grade ≥3 TRAE 3.9%; TIM-3 inhibitor TQB2618 ± penpulimab in NPC (NCT05563480, n=17): ORR 0%, median PFS 1.6 months PMID:24952746.

Resistance mechanisms

Cancer types (linked)

Sources

This page was processed by entity-page-writer on 2026-05-11.